A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis
Status:
Not yet recruiting
Trial end date:
2024-05-30
Target enrollment:
Participant gender:
Summary
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system.
In this study, children and teenagers with moderate to severe ulcerative colitis will be
treated with vedolizumab.
The main aim of the study is to check if participants achieve remission after treatment with
vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no or
limited signs of disease.
Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have a
clinical response will receive 1 of 3 doses of vedolizumab once every 8 weeks. They will
receive the same dose every time.